This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Boehringer Ingelheim Hellas.
Reference
Gourzoulidis G, et al. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece. Clinical Drug Investigation : 9 Mar 2021. Available from: URL: https://doi.org/10.1007/s40261-021-01013-w
Rights and permissions
About this article
Cite this article
Empagliflozin highly cost-effective treatment option for patients with T2DM and CVD. PharmacoEcon Outcomes News 874, 15 (2021). https://doi.org/10.1007/s40274-021-7558-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7558-6